These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 9636583)

  • 1. Comparison of quadruple induction including ATG or IL-2R antibody with FK506-based therapy after liver transplantation.
    Langrehr JM; Schneller A; Guckelberger O; Lohmann R; Neumann U; Jonas S; Klupp J; Settmacher U; Knoop M; Bechstein WO; Neuhaus PJ
    Transplant Proc; 1998 Jun; 30(4):1439-40. PubMed ID: 9636583
    [No Abstract]   [Full Text] [Related]  

  • 2. Chronic rejection after orthotopic liver transplantation is increased under induction therapy with interleukin-2 receptor antibody BT563.
    Langrehr JM; Lohmann R; Raakow R; Jonas S; Klupp J; Bechstein WO; Neuhaus R; Neuhaus P
    Transplant Proc; 2001 May; 33(3):2290-1. PubMed ID: 11377531
    [No Abstract]   [Full Text] [Related]  

  • 3. IL-2 receptor antibody induction increases the risk for chronic rejection after liver transplantation.
    Langrehr JM; Lohmann R; Guckelberger O; Müller AR; Raakow R; Nüssler NC; Klupp J; Pfitzmann R; Jonas S; Settmacher U; Steinmüller T; Neuhaus P
    Transplant Proc; 2001; 33(1-2):1433-4. PubMed ID: 11267360
    [No Abstract]   [Full Text] [Related]  

  • 4. Interleukin-2 receptor antibody versus antithymocyte globulin as part of quadruple induction therapy after orthotopic liver transplantation: a randomized study.
    Langrehr JM; Guckelberger O; Nüssler N; Radtke A; Lemmens HP; Jonas S; Lohmann R; Tullius S; Steinmüller T; Raakow R; Neumann U; Knoop M; Bechstein WO; Neuhaus P
    Transplant Proc; 1996 Dec; 28(6):3204. PubMed ID: 8962241
    [No Abstract]   [Full Text] [Related]  

  • 5. Quadruple induction therapy including antithymocyte globulin or interleukin-2 receptor antibody or FK 506-based induction therapy after liver transplantation.
    Lohmann R; Langrehr JM; Klupp J; Neumann U; Guckelberger O; Müller AR; Nüssler NC; Jonas S; Lang M; Settmacher U; Bechstein WO; Neuhaus PJ
    Transplant Proc; 1999; 31(1-2):380. PubMed ID: 10083151
    [No Abstract]   [Full Text] [Related]  

  • 6. Quadruple induction immunosuppression after liver transplantation with IL-2 receptor antibody (BT 563) is equally effective and better tolerated than ATG induction therapy.
    Neuhaus B; Keck H; Bechstein WO; Blumhardt G; Langrehr JM; Wiens M; Lemmens HP; Lohmann R; Schlag H; Thalmann U
    Transplant Proc; 1993 Feb; 25(1 Pt 1):587-9. PubMed ID: 8438426
    [No Abstract]   [Full Text] [Related]  

  • 7. Selective immunosuppression with FK 506, anti-IL-2R, and anti-ICAM-1 monoclonal antibodies: contrasting effects after liver and small bowel transplantation in rats.
    Otto C; Gasser M; Gassel HJ; Steger U; Timmermann W; Meyer D; Ulrichs K; Thiede A
    Transplant Proc; 1998 Aug; 30(5):2161-2. PubMed ID: 9723426
    [No Abstract]   [Full Text] [Related]  

  • 8. Quadruple induction immunosuppression after liver transplantation with interleukin-2 receptor antibody (BT 563) is equally effective and better tolerated than antithymocyte globulin induction therapy.
    Neuhaus P; Bechstein WO; Blumhardt G; Steffen R; Keck H; Lemmens P; Langrehr JM; Schlag H
    Transplant Proc; 1993 Apr; 25(2):1940-1. PubMed ID: 8470234
    [No Abstract]   [Full Text] [Related]  

  • 9. Quadruple immunosuppression including a new IL-2-receptor antibody and the incidence of infections after liver transplantation.
    Raakow R; Steffen R; Knoop M; Blumhardt G; Lemmens P; Wiens M; Keck H; Neuhaus P
    Transpl Int; 1992; 5 Suppl 1():S168-9. PubMed ID: 14621765
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interleukin-2 receptor antibody vs ATG for induction immunosuppression after liver transplantation: initial results of a prospective randomized trial.
    Lemmens HP; Langrehr JM; Bechstein WO; Blumhardt G; Keck H; Lüsebrink R; Knoop M; Lohmann R; Tullius S; Lobeck H
    Transplant Proc; 1995 Feb; 27(1):1140-1. PubMed ID: 7878826
    [No Abstract]   [Full Text] [Related]  

  • 11. Anti-IL-2 receptor BT563 versus placebo: a randomized trial for induction therapy after liver transplantation.
    Glanemann M; Langrehr JM; Raakow R; Guckelberger O; Lohmann R; Klupp J; Lobeck H; Schlag H; Keck H; Bechstein WO; Settmacher U; Neuhaus P
    Transplant Proc; 1998 Aug; 30(5):2159-60. PubMed ID: 9723425
    [No Abstract]   [Full Text] [Related]  

  • 12. Quadruple versus dual tacrolimus-based induction after liver transplantation: a prospective, randomized trial.
    Langrehr JM; Klupp J; Junge G; Jonas S; Neuhaus R; Bechstein WO; Neuhaus P
    Transplant Proc; 2001 May; 33(3):2330-1. PubMed ID: 11377549
    [No Abstract]   [Full Text] [Related]  

  • 13. A prospective randomized trial comparing interleukin-2 receptor antibody versus antithymocyte globulin as part of a quadruple immunosuppressive induction therapy following orthotopic liver transplantation.
    Langrehr JM; Nüssler NC; Neumann U; Guckelberger O; Lohmann R; Radtke A; Jonas S; Klupp J; Steinmüller T; Lobeck H; Meuer S; Schlag H; Lemmens HP; Knoop M; Keck H; Bechstein WO; Neuhaus P
    Transplantation; 1997 Jun; 63(12):1772-81. PubMed ID: 9210503
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcome following orthotopic liver transplantation in HBsAg-positive patients using short- or long-term immunoprophylaxis.
    Lemmens HP; Langrehr JM; Blumhardt G; Lohmann R; Knoop M; Verschl J; Schattenfroh N; Neuhaus R; Hopf U; Bechstein WO
    Transplant Proc; 1994 Dec; 26(6):3622-3. PubMed ID: 7527983
    [No Abstract]   [Full Text] [Related]  

  • 15. Risk and benefit of antibody induction therapy in combination with tacrolimus immunosuppression after liver transplantation.
    Klupp J; Bechstein WO; Pratschke J; Tullius SG; Gebhard A; Lobeck H; Langrehr JM; Neuhaus R; Neuhaus P
    Transplant Proc; 1998 Jun; 30(4):1443-4. PubMed ID: 9636585
    [No Abstract]   [Full Text] [Related]  

  • 16. FK506 for primary and rescue therapy following liver transplantation.
    Platz KP; Mueller AR; Zytowski M; Lobeck H; Neuhaus P
    Transplant Proc; 1998 Jun; 30(4):1409-10. PubMed ID: 9636570
    [No Abstract]   [Full Text] [Related]  

  • 17. Interleukin-2 receptor antibody therapy.
    Ascher NL
    Liver Transpl Surg; 1997 Nov; 3(6):643-4. PubMed ID: 9404968
    [No Abstract]   [Full Text] [Related]  

  • 18. Comparison of quadruple immunosuppression after liver transplantation with ATG or IL-2 receptor antibody.
    Neuhaus P; Bechstein WO; Blumhardt G; Wiens M; Lemmens P; Langrehr JM; Lohmann R; Steffen R; Schlag H; Slama KJ
    Transplantation; 1993 Jun; 55(6):1320-7. PubMed ID: 8516819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BT563 significantly decreases sIL-2R plasma levels despite acute allograft rejection.
    Mueller AR; Platz KP; Steinmüller T; Nüssler N; Neumann U; Gerlach H; Stoll C; Bechstein WO; Neuhaus P
    Transplant Proc; 1996 Dec; 28(6):3103-5. PubMed ID: 8962203
    [No Abstract]   [Full Text] [Related]  

  • 20. Impact of primary immunosuppression on the incidence of infectious complications after orthotopic liver transplantation.
    Lohmann R; Langrehr JM; Raakow R; Jonas S; Klupp J; Steinmüller T; Neuhaus R; Neuhaus P
    Transplant Proc; 2000 Nov; 32(7):2229-30. PubMed ID: 11120145
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.